Cargando…

Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients

BACKGROUND: The association between body mass index (BMI) and the overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial and unclear, METHOD: A total of 2010 patients from a high-volume center were enrolled in the study. The OS of PDAC patients was evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Ningzhen, Jiang, Yu, Qin, Kai, Chen, Hao, Deng, Xiaxing, Shen, Baiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656027/ https://www.ncbi.nlm.nih.gov/pubmed/34886801 http://dx.doi.org/10.1186/s12885-021-09056-0

Ejemplares similares

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis
por: Weng, Yuanchi, et al.
Publicado: (2020)

Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma
por: Wang, Chao, et al.
Publicado: (2022)

The impact of Omicron pandemic and COVID‐19 vaccination on the pancreatic adenocarcinoma patients
por: Fu, Ningzhen, et al.
Publicado: (2022)

Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEER Database
por: Wang, Weishen, et al.
Publicado: (2019)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER‐based analysis of 15,836 cases
por: Fu, Ningzhen, et al.
Publicado: (2021)

Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection
por: Chen, Haoda, et al.
Publicado: (2021)

The Necessity of Dissection of No. 14 Lymph Nodes to Patients With Pancreatic Ductal Adenocarcinoma Based on the Embryonic Development of the Head of the Pancreas
por: Qian, Lihan, et al.
Publicado: (2020)

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022)

Risk factors for and prognostic values of postoperative acute kidney injury after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A retrospective, propensity score‐matched cohort study of 1312 patients
por: Ji, Yuchen, et al.
Publicado: (2022)

H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma
por: Chen, Shi, et al.
Publicado: (2014)

Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
por: Cho, In Kuk, et al.
Publicado: (2020)

Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma
por: Wang, Xinjing, et al.
Publicado: (2018)

Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospective randomized controlled trial
por: WANG, Weishen, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease
por: Kruger, Deirdré, et al.
Publicado: (2022)

CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients
por: Sun, Yukun, et al.
Publicado: (2019)

Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival
por: Amantini, Consuelo, et al.
Publicado: (2019)

Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment
por: Xue, Meilin, et al.
Publicado: (2023)

Pancreatic adenocarcinomas with mature blood vessels have better overall survival
por: Katsuta, Eriko, et al.
Publicado: (2019)

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma
por: Wen, Chenlei, et al.
Publicado: (2020)

Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma
por: Li, Wanwan, et al.
Publicado: (2019)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Phosphomannose Isomerase High Expression Associated with Better Prognosis in Pancreatic Ductal Adenocarcinoma
por: Alipour, Zahra, et al.
Publicado: (2021)

Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma
por: Wu, Mengwei, et al.
Publicado: (2020)

Clinical importance of preoperative and postoperative prognostic nutritional index in patients with pancreatic ductal adenocarcinoma
por: Ikeguchi, Masahide, et al.
Publicado: (2019)

The Prognostic Value of Preoperative Geriatric Nutritional Risk Index in Patients with Pancreatic Ductal Adenocarcinoma
por: Hu, Si-Pin, et al.
Publicado: (2020)

The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection
por: Gruber, Elisabeth S., et al.
Publicado: (2020)

Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma
por: Li, Hongzhe, et al.
Publicado: (2017)

CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma – a quantitative analysis
por: Eilaghi, Armin, et al.
Publicado: (2017)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
por: Prinz, Christian, et al.
Publicado: (2022)

Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients
por: Xiao, Yuanyuan, et al.
Publicado: (2017)

Prediction of overall survival in patients with pancreatic ductal adenocarcinoma: histogram analysis of ADC value and correlation with pathological intratumoral necrosis
por: Noda, Yoshifumi, et al.
Publicado: (2022)

Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy
por: Mortoglou, Maria, et al.
Publicado: (2021)

Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma
por: Satoi, Sohei, et al.
Publicado: (2019)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

Health‐related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenocarcinoma
por: Ji, Yuchen, et al.
Publicado: (2023)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pbtmap5b6pods9kopurdve8o3h